focus -WSS

focus

author：knowledge 2025-10-01 20:15:45 - browse：33

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： RSV vaccines may be linked to small increased risk of developing GBS

WSS

Kenai launches with $82 million for Parkinson’s stem cell therapy

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

How to fix the rural physician shortage in the U.S.

Pfizer highlights cancer drugs it thinks could reignite investor interest

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

A public scorecard can help hold safety

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

In age of alternative facts, a scholarly course on calling out crap

Google and Epic fight stronger regulation of AI in health care

As demand for Covid shots wanes, Moderna seeks its next success

FDA approves RSV monoclonal antibody for infants, toddlers

Medical records are filled with copy

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Wildfire smoke exposes gaps in outdoor worker protections

Startup Neumora takes a novel depression drug to Phase 3

Wikipedia

Custom gene therapy hints at new path for rare disease treatments

Obesity now affects over 1 billion people worldwide, study finds

Why getting cancer drugs just got harder for rural patients

Medicare has a new plan to address drug shortages

Flu vaccine offering decent levels of protection this winter, new data show

RaDonda Vaught to speak at CommonSpirit event on patient safety

entertainment

entertainment

focus

knowledge